Please assess the completion status of the following clinical trial:

Trial Title: LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks~* Fasting LDL-C ≥ 85 mg/dL~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization~* Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (Glycosyated Hemoglobin (HbA1c) \> 8.5%)~* Uncontrolled hypertension~* New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
- Placebo Q4W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
- Evolocumab 70 mg Q2W (Type: EXPERIMENTAL): Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 105 mg Q2W (Type: EXPERIMENTAL): Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 140 mg Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 280 mg Q4W (Type: EXPERIMENTAL): Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg Q4W (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg Q4W (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).